---
marp: true
theme: uncover
paginate: true
backgroundColor: #ffffff
style: |
  section { font-family: 'Helvetica', sans-serif; text-align: left; }
  header { color: #2c3e50; font-weight: bold; }
  footer { font-size: 15px; color: #7f8c8d; }
  .columns { display: grid; grid-template-columns: repeat(2, minmax(0, 1fr)); gap: 1rem; }
  .highlight { color: #d35400; font-weight: bold; }

title: Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics
footer: "PHA 548 | Hampton University | PY1 PharmD"
---

# üß¨ Medicinal Chemistry: Benzodiazepine Sedative-Hypnotics

**Course:** PHA 548 Pharmacology & Medicinal Chemistry  
**Instructor:** Sidney Bolden, Jr., Ph.D.

---

## üéØ Learning Objectives

By the end of this lecture, you should be able to:

1. **MOA:** Describe benzodiazepine interaction at the $GABA_A$ Œ±‚ÄìŒ≥ interface.  
2. **SAR:** Identify structural features that drive potency, affinity, and selectivity.  
3. **PK/Metabolism:** Predict metabolic pathways and duration of action based on key substituents.  
4. **Innovation:** Evaluate ‚Äúsoft drug‚Äù design using remimazolam as a modern example.

---

## $GABA_A$ Receptor: The Biological Target

<div class="columns">
<div>

**Key Concepts**

- **Type:** Pentameric ligand-gated $Cl^-$ channel  
  - Typical stoichiometry: 2Œ±, 2Œ≤, 1Œ≥  
- **BZDs bind:** at the **Œ±‚ÄìŒ≥ subunit interface**  
- **Mechanism:** Increase the **frequency** of GABA-induced channel opening  
- **Safety:** Require GABA presence ‚Üí lower risk vs. barbiturates at therapeutic doses  

</div>
<div>

![GABAA binding site](figures/BZ_Allosteric_Binding.jpg)

</div>
</div>

---

## üõ†Ô∏è The BZD Pharmacophore

**Core scaffold: 5-phenyl-1,4-benzodiazepine-2-one**

<div class="columns">
<div>

**Essential Anchors**

1. **Ring A:** Aromatic ring; C7 electronegative substituent (e.g., $Cl$, $Br$, $NO_2$)  
2. **Ring B:** C2 carbonyl and diazepine ring (H-bonding and geometry)  
3. **Ring C:** Phenyl ring providing aromatic $\pi$‚Äì$\pi$ stacking in the binding pocket  

> Loss or major distortion of these elements usually leads to large loss of BZD activity.

</div>
<div>

![Backbone](figures/BZ_backbone.jpg)

</div>
</div>

---

## SAR ‚Äî High-Yield ‚ÄúCheat Sheet‚Äù

| Site | Preferred / Required Feature | MedChem Effect |
| :--- | :--- | :--- |
| **C7 (Ring A)** | Electronegative ($Cl$, $Br$, $NO_2$) | ‚Üë Affinity and potency |
| **N1 / Ring B** | Small substituents (or H) | Modulates PK; large groups can reduce activity |
| **C3 (Ring B)** | **‚ÄìOH group** (3-OH BZDs) | ‚Üë Phase II clearance; shorter duration |
| **C2‚Ä≤ (Ring C)** | o-Halogenation ($F$, $Cl$) | ‚Üë Lipophilicity, ‚Üë CNS penetration, often ‚Üë potency |
| **C4‚Ä≤ (Ring C)** | Bulky substituents | Steric clash; often **abolishes or greatly reduces activity** |

> PY1 Focus: C7, C3, and Ring C substitutions are the most testable and clinically relevant.

---

## üß™ Metabolism: The Oxidative Liability  
### Example: Flurazepam (Long-Acting)

- **Pathway:** CYP3A4-mediated N-dealkylation and oxidation  
- **Consequence:** Formation of **long-acting active metabolites**  
- **Clinical:**  
  - Extended sedation  
  - Daytime drowsiness  
  - Increased fall/cognitive risk in elderly

![Flurazepam metabolism](figures/flurazepam_metabolism.jpg)

---

## ‚ö° Metabolism: The 3-OH Advantage

**3-OH Benzodiazepines**  
(e.g., **Temazepam**, Oxazepam, Lorazepam)

- **Structural feature:** C3 **‚ÄìOH** group  
- **Pathway:** Direct **Phase II glucuronidation** (UGTs)  
- **Result:**  
  - Minimal Phase I oxidative metabolism  
  - No long-acting active metabolites  
  - **Temazepam** ‚Äî sedative-hypnotic with safer use in hepatic impairment  

![Temazepam metabolism](figures/Temazepam_metabolism.jpg)

> Note: Lorazepam and oxazepam are not usually used as hypnotics, but share the same 3-OH / Phase II metabolism concept.

---

## üöÄ Modern Innovation: Remimazolam (Byfavo)

**‚ÄúSoft Drug‚Äù Evolution of the Benzodiazepine Scaffold**

- **Core:** Triazolobenzodiazepine-like pharmacophore (preserves GABAA binding)  
- **Design Feature:** Carboxylic **ester side chain** built in as a ‚Äúsoft spot‚Äù  
- **Metabolism:**  
  - Rapid hydrolysis by **tissue esterases**  
  - Minimal dependence on CYPs (CYP-mediated routes are minor)  
- **Benefit:**  
  - Predictable, **ultra-short** sedation  
  - Useful for procedural sedation (e.g., endoscopy)  
  - Reduced risk of accumulation even with repeated dosing  

![Remimazolam](figures/Remimazolam-metabolism.jpg)

---

## üìä Comparative PK Summary

| Drug | Dominant Metabolic Route | PK Outcome (Simplified) |
| :--- | :--- | :--- |
| **Flurazepam** | CYP3A4 (N-dealkylation, oxidation) | Long-acting active metabolites; residual sedation |
| **Estazolam** | Oxidation of triazolo-BZD | Intermediate duration; fewer long-acting metabolites |
| **Temazepam** | Direct Phase II conjugation (3-OH) | Relatively rapid clearance; shorter duration |
| **Remimazolam** | Ester hydrolysis by esterases | Ultra-short duration; soft-drug behavior |

---

## üß† PY1 Critical Thinking Exercise

**Predict the outcome of these structural changes (qualitatively):**

1. **Remove C7‚ÄìCl:**
   - Expect **markedly reduced potency/affinity** at $GABA_A$ BZD site.

2. **Add bulky para-substitution on Ring C (4‚Ä≤ position):**
   - Likely **abolishes or severely reduces activity** due to steric clash.

3. **Add a fused triazolo ring (triazolobenzodiazepine):**
   - Often **increases potency**  
   - Provides **metabolic shielding**, reducing some oxidative pathways.

> Be prepared to explain your reasoning using SAR logic (electronic, steric, lipophilicity, and metabolism effects).

---

# Questions?

**Next Lecture:** Non-benzodiazepine hypnotics (‚ÄúZ-drugs‚Äù) and comparison of pharmacophore vs. BZDs.
